Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Gregg Boehmer
- Sector
- Consumer Cyclical
- Industry
- Auto - Parts
- Employees
- 1
- Beta
- 1.50
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1045.90
Financials
Revenue
$0.00-100.0%Net Income
$-76.2KEBITDA
$-76.2KFree Cash Flow
—EPS (diluted)
$0.00Shares Outstanding (diluted)
4.75B+8866.7%Operating Expenses
$76.2KCash & Debt
$6.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-2.69M | $0.00 |
| 2022 | $2.19M | $-1.35M | $-0.00 |
| 2021 | $5.71M | $3.73M | $0.00 |
| 2019 | $1.01M | $-1.20M | $-0.00 |
| 2018 | $91.1K | $-1.32M | $-0.09 |
| 2017 | $24.2K | $-10.0K | $-0.00 |
| 2016 | $30.9K | $-32.9K | $-0.00 |
| 2015 | $43.1K | $-11.1K | $-0.00 |
Valuation
OPTIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·4d ago·Neutral
Optimi Health Outlines 2027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSD; Announces Shares-for-Debt Settlement Proposed OPTI-101 protocol amendment converts the single-arm, open-label Phase 2 trial into a randomized, double-blind Phase 2b in severe major depressive disorder, enhancing statistical power; dosing expected Q1 2027 with topline data expected in 2028
View source ↗ - Newsglobenewswire.com·46d ago·Negative
Optimi Health to Present at the ThinkEquity Conference VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced that it will participate in the ThinkEquity Conference taking place on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a…
View source ↗ - Newsglobenewswire.com·60d ago·Negative
… Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company's cGMP facility in Princeton, British Colum…
View source ↗ - Newsglobenewswire.com·61d ago·Negative
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D.
View source ↗ - Newsglobenewswire.com·100d ago·Negative
Optimi Health Establishes Discretionary Equity Facility VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which th…
View source ↗
Congress trades
No disclosed congressional trades in OPTI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
